Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy

Alice Hours†, Aullene Toussaint1,2,3†, Victoire De Castelbajac2,4, Camille Sautter1, Julie Borghese3, Sophie Frank2, Florence Coussy2, Enora Laas1,2, Beatriz Grandal3, Elise Dumas3, Eric Daoud3, Julien Guerin5, Thomas Balezeau6, Jean-Guillaume Feron1, Virginie Fourchotte1, Youlia Kirova6, Florence Lerebours3, Jean-Yves Pierga3, Eugénie Guillot1, Pietro Santulli7, Michael Gryenberg8,9, Charlotte Sonigo8, Emmanuel Reyrat10, Pauline Sobinet-Oudot11, Fabien Reyat1,3* and Anne-Sophie Hamy1,2,3*†

1 Department of Surgery, Institut Curie, University Paris, Paris, France, 2 Department of Medical Oncology, Institut Curie, University Paris, Paris, France, 3 Department of Radiation Therapy, Institut Curie, Paris, France, 4 Department of Obstetrics and Gynecology, Hôpital Cochin, University Paris, Paris, France, 5 Data Factory, Institut Curie, Paris, France, 6 Department of Radiology, INSERM, U932 Immunity and Cancer, Paris, France, 7 Department of Obstetrics and Gynecology, Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, University Paris, Paris, France, 8 Department of Obstetrics and Gynecology, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris Sud, Assistance Publique - Hôpitaux de Paris, Clamart, France, 9 Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Bondy, France, 10 Department of Data and Informatics, Unicancer, Paris, France, 11 Department of Medical Oncology, Godinot Institute, Reims, France

Purpose: Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility preservation (FP).

Material and Methods: We analyzed consecutive BC patients treated by chemotherapy at Institut Curie from 2011-2017 and aged 18-43 years at BC diagnosis. The discussion of FP was classified in a binary manner (discussion/no discussion), based on mentions present in the patient’s electronic health record (EHR) before the initiation of chemotherapy. The associations between FP discussion and the characteristics of patients/tumors and healthcare practitioners were investigated by logistic regression analysis.

Results: The median age of the 1357 patients included in the cohort was 38.7 years, and median tumor size was 30.3 mm. The distribution of BC subtypes was as follows: 702 luminal BCs (58%), 241 triple-negative breast cancers (TNBCs) (20%), 193 HER2+/HR+ (16%) and 81 HER2+/HR- (6%). All patients received chemotherapy in a neoadjuvant (n=611, 45%) or adjuvant (n= 744, 55%) setting. A discussion of FP was mentioned for 447 patients (33%). Earlier age at diagnosis (discussion: 34.4 years versus no discussion: 40.5 years), nulliparity (discussion: 62% versus no discussion: 38%), and year of BC...
Breast cancer (BC) is the most frequent cancer in women (1), and about 7% of BC diagnoses concern women under the age of 40 years (2). Survival rates are continually improving, thanks to advances in early detection and treatment. Mean age at first pregnancy is continuing to increase, due to changes in society, and the question of fertility and pregnancy after BC is therefore being raised increasingly frequently (3).

Oncological treatments may impair the fertility of premenopausal patients with BC. Chemotherapy may induce premature ovarian failure, depending on the woman’s age and the drugs used, their dose and the duration of treatment (4). Adjuvant endocrine therapy, which is generally recommended for five years in patients with hormone-responsive cancers, can also delay parenthood, due to the potential teratogenicity of the treatment (5).

A number of fertility preservation (FP) techniques are available, and the freezing of embryos or oocytes after controlled stimulation for future in vitro fertilization procedures is the most frequently used (6). If this is unfeasible or if ovarian stimulation is contraindicated, ovarian tissue cryopreservation of oocyte/embryo vitrification after the in vitro maturation of oocytes recovered from small antral follicles may be used as an alternative (7).

Previous studies have suggested that many BC patients are interested in maintaining their future fertility at the time of diagnosis. However, they do not systematically receive information about the fertility risks of treatment and fertility preservation options (8), with such discussion occurring in 30 to 70% of patients (9, 10). The American Society of Clinical Oncology recommends that physicians question newly diagnosed cancer patients as soon as possible about their desire for future fertility, and that interested patients be immediately referred to specialists in fertility preservation techniques, when appropriate (6). In France, the National Cancer Plan 2014-2019 highlighted the need for systematic and appropriate information on fertility preservation and promoted the concept of oncofertility (11).

Publications to date on the factors predictive of FP discussion in BC are mostly limited to small qualitative studies. Disparities in referral patterns and access to FP have been observed with respect to the demographic, clinical and socioeconomic characteristics of patients. A few studies have shown that patient age, and parity, the type of treatment, type of center and physician characteristics may affect the likelihood of FP discussion (9, 10, 12).

The objective of this study was to identify the factors associated with FP discussion in a population of women receiving chemotherapy for BC to improve patient counselling and timely access to FP services.

1 INTRODUCTION

Breast cancer (BC) is the most frequent cancer in women (1), and about 7% of BC diagnoses concern women under the age of 40 years (2). Survival rates are continually improving, thanks to advances in early detection and treatment. Mean age at first pregnancy is continuing to increase, due to changes in society, and the question of fertility and pregnancy after BC is therefore being raised increasingly frequently (3).

Oncological treatments may impair the fertility of premenopausal patients with BC. Chemotherapy may induce premature ovarian failure, depending on the woman’s age and the drugs used, their dose and the duration of treatment (4). Adjuvant endocrine therapy, which is generally recommended for five years in patients with hormone-responsive cancers, can also delay parenthood, due to the potential teratogenicity of the treatment (5).

A number of fertility preservation (FP) techniques are available, and the freezing of embryos or oocytes after controlled stimulation for future in vitro fertilization procedures is the most frequently used (6). If this is unfeasible or if ovarian stimulation is contraindicated, ovarian tissue cryopreservation of oocyte/embryo vitrification after the in vitro maturation of oocytes recovered from small antral follicles may be used as an alternative (7).

Previous studies have suggested that many BC patients are interested in maintaining their future fertility at the time of diagnosis. However, they do not systematically receive information about the fertility risks of treatment and fertility preservation options (8), with such discussion occurring in 30 to 70% of patients (9, 10). The American Society of Clinical Oncology recommends that physicians question newly diagnosed cancer patients as soon as possible about their desire for future fertility, and that interested patients be immediately referred to specialists in fertility preservation techniques, when appropriate (6). In France, the National Cancer Plan 2014-2019 highlighted the need for systematic and appropriate information on fertility preservation and promoted the concept of oncofertility (11).

Publications to date on the factors predictive of FP discussion in BC are mostly limited to small qualitative studies. Disparities in referral patterns and access to FP have been observed with respect to the demographic, clinical and socioeconomic characteristics of patients. A few studies have shown that patient age, and parity, the type of treatment, type of center and physician characteristics may affect the likelihood of FP discussion (9, 10, 12).

The objective of this study was to identify the factors associated with FP discussion in a population of women receiving chemotherapy for BC to improve patient counselling and timely access to FP services.

2 MATERIALS AND METHODS

2.1 Study Design

We analyzed a cohort of female patients with invasive BC aged between 18 and 43 years at the time of BC diagnosis, treated by chemotherapy at Institut Curie between January 1, 2011 and September 30, 2017. The upper limit of 43 years was chosen as this is the maximum age for reimbursement of assisted reproductive technology in France. In the study, we also used the 37 years as a cut-off point, as it has been shown that the age of 37 years is correlated with an accelerated disappearance of ovarian follicles in mid-life (13, 14). The study was conducted at two centers: the Institut Curie centers at Paris and Saint Cloud.

The cohort was constructed with the ConSore (15) search engine, a next-generation data analysis program developed by UNICANCER and allowing both requests with structured criteria and natural language processing for semantic searches (flow chart in Supplementary Table 1).

The exclusion criteria were another cancer before BC, distant metastases at diagnosis or within six months of diagnosis, bilateral breast cancer, refusal of treatment, hysterectomy, tubal sterilization or bilateral ovariectomy performed before diagnosis, patient refusal of the use of their data. We did not include patients who did not receive chemotherapy because in the 2 institutions in which the patients were treated that we analyzed, patients without chemotherapy were not offered fertility preservation procedures at the time of the study. All medical charts were manually verified from September 2017 to March
The study was approved by the Breast Cancer Study Group of Institut Curie and was conducted in accordance with institutional and ethical rules concerning research on tissue specimens and patients.

The objective of this study was to identify factors associated with discussion of FP in this population, and discussion of FP was used as the primary endpoint.

Under French regulations, written informed consent from patients was not required for this study. This study is a part of the young breast cancer project (YBCP), an institutional project aiming at characterizing BC care pathways in young women. It was approved by the breast cancer group and institutional board (approval 29th April 2019, reference cri-data DATA190136).

2.2 Patients
The data collected included age, parity and body mass index (BMI) at diagnosis, date of first consultation at Institut Curie, date of first biopsy showing malignant histological features, date of first chemotherapy, date of surgery, and BRCA status, when available. The date of the first consultation at Institut Curie was taken as the date of diagnosis.

2.3 Tumors
We retrieved the following tumor characteristics from the patients’ medical records: clinical T (size) stage and clinical N (nodal) status, immunohistochemical characteristics, such as the detection of estrogen receptors (ER), progesterone receptors (PR), HER2 status, Ki67 and histological grade. Cases were considered estrogen receptor (ER) - or progesterone receptor (PR)-positive (+) if at least 10% of the tumor cells expressed estrogen and/or progesterone receptors (ER/PR), in accordance with the guidelines used in France (16). HER2 expression was assessed by immunohistochemistry, with scoring according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Scores of 3+ were considered positive, scores of 1+/0 were considered negative (-). Tumors with scores of 2+ were subjected to further testing by FISH. HER2 gene amplification was defined according to ASCO/CAP guidelines (17). Based on immunohistochemical surrogates, pathological breast cancer subtypes were defined as follows: tumors positive for either ER or PR and negative for HER2 were classified as luminal; tumors positive for HER2 were considered HER2-positive BC; tumors negative for ER, PR, and HER2 were considered triple-negative BC (TNBC). Histological grade was determined according to the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system (18).

2.4 Treatments
Patients were treated according to national guidelines. Treatments were decided after multidisciplinary consultation meetings considering the characteristics of the patients and prognostic factors. For patients receiving neoadjuvant chemotherapy, surgery was performed four to six weeks after the end of chemotherapy. Trastuzumab was used in an adjuvant and/or neoadjuvant setting for HER2-positive breast cancer, in accordance with national guidelines. Most patients received adjuvant radiotherapy. Endocrine therapy (tamoxifen, aromatase inhibitor, and/or GnRH agonists) was prescribed when indicated. Every patient included in our study received chemotherapy (neoadjuvant and/or adjuvant).

2.5 Discussion About Fertility Preservation
Discussion about FP (FP discussion) — i.e. the delivery of information about the existence of fertility preservation procedure before chemotherapy — was assessed from electronic health records (EHR) as a binary variable (discussion/no discussion), and through a two-way process. Any discussion on damages on fertility induced by chemotherapy counted as “FP Discuss”. Only files with no information on fertility risks were classified as “FP No-Discuss". We first extracted specific string character patterns by text mining (TM), using specific key words associated with a high likelihood of FP discussion having occurred (“oncofertility”, “IVM”, “frozen oocytes”, “frozen embryos”, “(fertility)”, “ov* fragment preservation”, “ov* cryopreservation”, “ov* cryoconservation”), making it possible to identify the keyword concerned directly in the EHR. This text recognition method was developed and validated on two independent datasets and has been shown to have a better performance than the manual rereading of medical records to identify pregnancies (19). For patients for whom none of the keywords sought was found, we then manually checked all medical consultations between BC diagnosis and chemotherapy, from June to October, 2018.

2.6 Physicians
For any consultation with a medical doctor occurring between BC diagnosis and chemotherapy, demographic information about the physician was collected: sex (male versus female), age at consultation (junior < 45 years old versus senior > 45 years old) and type of specialty (surgeon, oncologist or radiotherapist), together with the rank of healthcare provider (ranging from 1 to 3). Once FP had been discussed with a healthcare provider, subsequent consultations were censored.

2.7 Fertility Preservation Procedures
Specific data concerning the procedures were retrieved from the three partner fertility preservation centers in the Parisian region: Jean Verdier Hospital in Bondy, Antoine Beclere Hospital in Clamart and Port Royal Hospital in Paris. We collected the following information: the final choice of the patients or the physician concerning FP procedures, recorded as a binary variable (yes/no), and the method used (oocyte or embryo vitrification after IVM or after controlled ovarian stimulation (COS), cortex cryopreservation).

2.8 Statistical Methods
The study population was described in terms of frequencies for qualitative variables, or medians and associated ranges for quantitative variables. For the comparison of continuous variables between groups, Wilcoxon-Mann-Whitney tests were used for groups including fewer than 30 patients, and for variables with multimodal distributions, and Student’s t tests were performed otherwise. Associations between categorical variables were assessed in chi-squared tests, or with Fisher’s exact test if at least one category included fewer than three
patients. A value of $P < 0.05$ was considered significant. Data were processed and statistical analyses performed with R software version 3.1.2 [www.cran.r-project.org, (R Foundation for Statistical Computing, 2009)]

Data were evaluated using multiple correspondence analysis (MCA). This method involves a multivariate analysis of categorical data and allows joint observation of a vast number of variables. By grouping various characteristics, it attempts to establish a profile capable of suggesting a predisposition to specific situations. Analysis was conducted with the package library (FactoMineR), which performs various mathematical procedures to define the best organization of variables and allocate variables into a four-quadrant plot divided by two axes. Results are interpreted by observation of clusters formed by variables. These clusters represent relations between the variables; the closer they are on the plot, the greater the frequency of their co-occurrence. The two axes separate variables plotted on the left upper quadrant from those in the right lower quadrant and those in the right upper quadrant from those in the left lower quadrant, establishing groups of variables with opposing profiles. It gives a representation of the absolute contribution of each variable according to its distance from the axis, both towards the positive and towards the negative side; the greater the distance, the greater its significance in the interpretation of results.

We used a mixed model combining mixed effects and random effects for the multivariate analysis. The fixed effects influence the mean of the variable of interest (FP discussion) and the random effects influence only the variance of that variable. We used this model based on the assumption that the observations in our database are not independent (i.e. that the occurrence of a FP discussion can be the same depending on the characteristics of the doctors and patients). Thus, the residual variance of the model is partitioned into a between two components: patients and doctors.

3 RESULTS
In total, 1357 patients were included in the study (Table 1). Median age at BC diagnosis was 38.7 years (range: 18-43 years). Most patients had one (21%) or more children (52%) at BC diagnosis, but 27% did not have children. Median tumor size was 30.3 mm, and 58% of the patients had luminal BCs. All patients received chemotherapy (neoadjuvant (45%)/adjuvant (55%) setting). The characteristics of the patients and their tumors differed according to age at BC diagnosis (Supplementary Table 2), with a larger number of patients having children (81% versus 66%), a larger proportion of luminal tumors (64% versus 54%), and a lower likelihood of receiving neoadjuvant as opposed to adjuvant chemotherapy (35% versus 52%) in older patients than in younger patients.

3.1 Factors Associated With Fertility Discussion
Some mention of FP discussion was found in the EHRs of 447 (33%) of the 1357 patients, whereas no such mention was not found in the EHRs of 909 patients (67%).

3.1.1 Patient-Related Factors
FP discussion was significantly associated with a younger age at BC diagnosis (median age 34 years versus 40 years, $p<0.001$) (Figure 1A), and were less likely to occur for obese patients (Figure 1B). Her frequency decreased with increasing numbers of children (Figure 1C) and increased over the time period of the cohort, reaching a plateau at about 45% after 2015 (Figure 1D).

Clinical stage ($p=0.05$) and neoadjuvant chemotherapy ($p<0.001$) were also significantly associated with FP discussion (Figures 1E, F respectively). Multiple component analysis identified two groups of patients and characteristics associated with fertility discussion (red ellipse: patients aged 37 years or older, with children at diagnosis, for whom there was no FP discussion; and blue ellipse: patients below the age of 37, with no children at diagnosis, for whom FP discussion occurred) (Figure 1G).

3.1.2 Doctor- and Center-Related Factors
In total, 2468 pre-chemotherapy consultations were retrieved from the EHRs (with surgeons $n=1280$; medical oncologists $n=1073$, and radiotherapy oncologists, $n=115$) (Table 2).

FP discussion was more frequently mentioned during the first pre-chemotherapy consultation, than during the following visits (discussed with the first practitioner $n=336$; second $n=92$; third $n=19$).

Doctors’ specialty was significantly associated with the likelihood of FP discussion. Surgeons were more likely to discuss FP with patients (22%) than medical oncologists (14%) and radiation oncologists (10%) (Figure 2A). Doctors’ age (Figure 2B) and sex (Figure 2C) were also significantly associated with FP discussion: junior doctors (21%) and female doctors (21%) were slightly more likely to discuss FP than senior doctors (17%) and male doctors (15%), respectively. The site where patients received their treatment (center 1 versus center 2) (Figure 2D) was not significantly associated with the likelihood of FP discussion ($p=0.14$).

Multiple correspondence analysis identified two groups of physicians and characteristics associated with FP discussion (red ellipse: oncologists and male physicians not discussing FP with patients; blue ellipse: surgeons and female physicians discussing FP with patients) (Figure 2E).

3.1.3 Factors Associated With FP Discussion in Multivariate Analysis
After multivariate analysis with the mixed model, fertility discussion was significantly associated with younger age, number of children before BC diagnosis, physicians’ gender and physicians’ specialty (Table 3).

3.2 Factors Associated With the Performance of Fertility Preservation Procedures (FPPs)
FP procedures were performed in 262 of the 1357 patients (19%). Seventeen patients received treatment with LHRH analogs. The main factor associated with the occurrence of FPPs was the occurrence of FP discussion (only three patients underwent FPPs without prior FP discussion).
Out of 447 patients who had a FP discussion, 259 patients (58%) had a FP procedure and 188 (42%) didn’t have (Table 4). The factors significantly associated with the realization of a FPP in FP discussion group were age (Figure 3A), and previous children (Figure 3B). The type of chemotherapy was not associated with PPF (Figure 3C). The MCA clustered patients into two distinct groups, with FP discussion, already having children, and age as the major factors explaining the performance of a FPP (Figure 3D).

Most patients (n=175) underwent IVM, and one third (n=84) had at least one COS. The factors associated with the type of FPP (Supplementary Table 3) were mostly related to the chemotherapy setting with COS used in a neoadjuvant setting in only six out of 146 patients.

### 4 DISCUSSION

This large, real-life study found that the rates of the discussion of fertility preservation (FP) were low (33%) in a consecutive series of 1,357 female breast cancer patients exposed to gonadotoxic chemotherapy. Furthermore, we discussed the correlation between FP discussion and the characteristics of patients/
tumors and healthcare practitioners. We found that younger age, number of children before breast cancer diagnosis, physicians' gender and physician's specialty were independent predictors of FP discussion. We also found an increased likelihood of FP discussion over time. In general, the findings in the present study support the above-mentioned conclusion. The results of our study confirm and reinforce previous findings from the literature.

One of its key findings is that FP discussion was mentioned in only one third of EHRs. These rates lie in the lower part of the range of published values, which generally range from 30 to 70% (9, 12, 20). There are several possible reasons for these low rates. First, we included patients up to 43 years old, and patients 40 y.o. or above represented 41% of the cohort. When focusing only in the subpopulation of patients below 40, the discussion rate increased to 51%. Second, this cohort study began in 2011, a
### TABLE 2 | Likelihood of FP discussion according to physician characteristics and center (n=2468).

| Variable name                     | Level       | Overall 2468 | FP Discussion 447 | No FP Discussion 2021 | p     |
|-----------------------------------|-------------|--------------|-------------------|-----------------------|-------|
| Specialty                         | Oncologist  | 1073 (43%)   | 150 (14%)         | 923 (86%)             | <0.001|
|                                   | Radiotherapy oncologist | 115 (5%) | 12 (10%)         | 103 (90%)             |       |
|                                   | Surgeon     | 1280 (52%)   | 285 (22%)         | 995 (78%)             |       |
| Age                               | Junior      | 937 (38%)    | 193 (21%)         | 744 (79%)             | 0.017 |
|                                   | Senior      | 1521 (62%)   | 254 (17%)         | 1267 (83%)            |       |
| Sex                               | Female      | 1292 (52%)   | 274 (21%)         | 1018 (79%)            | <0.001|
|                                   | Male        | 1169 (48%)   | 173 (15%)         | 996 (85%)             |       |
| Treatment center                  | Center 1    | 1454 (59%)   | 287 (20%)         | 1167 (80%)            | 0.143 |
|                                   | Center 2    | 1014 (41%)   | 160 (16%)         | 854 (84%)             |       |

Values in bold are the significant values.

### FIGURE 2 | Factors associated with fertility preservation Discussion. (A) Doctors’ specialty; (B) Doctors’ age; (C) Doctors’ sex; (D) Treatment Center; (E) MCA with FP discussion*. (E) The red ellipse represents the concentration of patients who did have discussion about fertility preservation, whereas the blue ellipse represents the concentration of patients who discussed fertility preservation with a physician.
study con-"fi-

to 7% in women over the age of 40 years. The mixed model of our

discussion was 35% in women aged 35 years or older, falling

in practices over time indicates an increase in the awareness of healthcare practitioners. A plateau was

nevertheless reached in 2015, and the proportion of patients for whom FP was discussed never exceeded 50%. This result is consistent with previous studies (10) indicating a significant, but nevertheless incomplete, improvement in practices. Another possible reason is that the Institut Curie is a specialist cancer center focusing purely on oncology care. Thus, unlike multispecialty clinics, it does not have its own gynecology or reproductive biology department.

Our findings confirm that several patient-related factors are associated with the likelihood of FP discussion, as summarized in Supplementary Table 4 (BC) and Supplementary Table 5 (all cancer types). Earlier age at diagnosis was significantly associated with a greater likelihood of FP discussion (8, 9). The frequency of FP discussion was 35% in women aged 35 years or older, falling to 7% in women over the age of 40 years. The mixed model of our study confirms the impact of age on FP discussion. Age at diagnosis is a well-known, important factor associated with FP discussion, and this association has been found to be significant in most studies. This finding is nevertheless a matter of concern, because the proportion of women diagnosed with BC increases steadily with age, and most “young” BC patients are already at least 37 years old at BC diagnosis. There are currently no guidelines specifying that such discussion is dispensable for women over the age of 37 years. For the use of vitrified oocytes, French guidelines consider that it is imperative to take into account obstetrical morbidity, which increase with age (after 45 years, pregnancy is at high risk of complications and even more after the age of 50 years) (21). Not all patients will be eligible for FP, but it is essential to have a discussion with them about their options and about post-cancer infertility.

Consistent with another study (20), we found that nulliparity was significantly associated with FP discussion. Such discussion took place for only 17% for patients who already had more than one child at diagnosis. Thewes et al. reported that about 70% of 228 BC patients under the age of 45 years wished to have a child after their treatment was completed (8). Marklund et al. (22), analyzed a cohort of 1275 BC patients and found that 171 patients (33%) had a live birth after the end of treatment, and that 63% of these patients already had at least one child at diagnosis.

In our study, no factor related to BC disease (clinical T stage, lymph node status, SBR grade, BC subtype, histological type) was found to be significantly associated with the likelihood of FP discussion. Conflicting results have been reported (8), but several studies (10) have suggested that early-stage disease is more frequently associated with FP discussion. We did not include bilateral breast cancer which makes more complex statistical analyses as it requires the use of multilevel models, and it causes difficulties in attributing relapse to one or to the other side. Furthermore, it is very unlikely that the results are biased because synchronous bilateral breast cancers represent 1-3% (23). In terms of treatment, FP was more frequently discussed in the group of patients receiving neoadjuvant chemotherapy than in patients receiving adjuvant chemotherapy, but this was highly probably due to age acting as a confounding factor, because it was very significantly associated with the chemotherapy setting. We did not include patients who did not receive chemotherapy, but we must highlight that the patients who did not receive chemotherapy represent a very minority in this age group (15 to 20%). We found no impact of type of chemotherapy, hormone therapy, or radiation therapy, consistent with the findings of other studies (9, 24). However, FP is an important subject in this context, because hormone therapy can delay pregnancy plans by at least two to three years.

Several practitioner-related factors were associated with the likelihood of FP discussion, including specialty in particular. Surgeons were the most likely to discuss FP with their patients, followed by medical oncologists and then radiotherapists. We also identified the sex and age of the medical practitioner as significantly associated with the likelihood of FP discussion. Korkidakis et al. (20) analyzed a cohort of 4,452 breast cancer patients aged 15-39 years before chemotherapy treatment and obtained similar results, with female physicians and surgeons the most likely to discuss FP with their patients. Covelli et al. (25) investigated the barriers to physicians discussing fertility and found that physicians often assigned responsibility for fertility counselling to other clinicians and felt a lack of confidence in their ability to initiate FP discussion. Patel et al. (26) found that multi-specialty clinics had lower rates of FP counseling concerning fertility risk than single-specialty clinics.
One possible reason for this difference may be a lack of clear designation of the doctor responsible for discussing the infertility risk associated with chemotherapy. Multicenter studies have identified regional disparities in information about FP, and differences between oncology centers (10), but we found no significant differences between the cancer centers in our study.

Finally, we confirm the crucial importance of FP discussion for favoring the performance of FPPs. Only three of the 262 patients who underwent FP procedures had not previously discussed FP with their doctors. Our data therefore indicate that a lack of discussion about FP during in-house consultations severely impedes patient choice as to whether to undergo FPPs. However, almost one third (188/447) of the patients who received information about FP chose not to undergo FPPs, or were not eligible for the procedures. We found the same factors associated with the FP procedure in the group of patients who had a FP discussion: age and parity. Previous studies analyzing annual income or health insurance as possible factors influencing discussion about FP found no association with these factors (9), which can be ruled out in our study because all the patients were covered by a universal social security system guaranteeing the full reimbursement of FP fees, up to 43 years.

Our study has several strengths, in particular, the inclusion of a large number of patients and doctors, allowing an analysis of a multitude of variables. However, it also has limitations, such as its retrospective nature, in particular. Information on the FP discussion was retrospectively obtained from the patient’s electronic health record. Since some doctors may not record their discussion with patients about FP in the electronic health record system, results from this study may underestimate the rates of FP discussion. The healthcare providers play an important role in the discussion of fertility preservation. However, less than 50% of the patients had FP

### TABLE 4 | Performance of fertility preservation procedures (FPPs) as a function of patient with FP discussion characteristics (n = 447).

| Variable name                      | Level n | Overall 447 | FP Procedure 259 (58%) | No FP Procedure 188 (42%) | p       |
|------------------------------------|---------|-------------|------------------------|---------------------------|---------|
| Age (year)                         | [0-30]  | 72          | 63 (88%)               | 9 (12%)                   | <0.001  |
|                                   | [30-35] | 173         | 118 (68%)              | 55 (32%)                  |         |
|                                   | [35-40] | 162         | 75 (46%)               | 87 (54%)                  |         |
|                                   | 40+     | 40          | 3 (8%)                 | 37 (92%)                  |         |
| Age (mean)                         | 34.2 (4.1) | 32.7 (4.7) | 36.9 (3.7)            | <0.001                    |
| Number of children                 | 0       | 231         | 176 (76%)              | 55 (24%)                  | <0.001  |
|                                   | 1       | 99          | 51 (52%)               | 48 (48%)                  |         |
|                                   | More than 1 | 117       | 32 (27%)               | 85 (73%)                  |         |
| BMI                                | <18.5   | 29          | 15 (52%)               | 14 (48%)                  | 0.543   |
|                                   | 18.5-24.9 | 302        | 181 (60%)              | 121 (40%)                 |         |
|                                   | 25-29.9 | 88          | 46 (52%)               | 42 (48%)                  |         |
|                                   | >=30    | 20          | 12 (60%)               | 8 (40%)                   |         |
| BMI (mean)                         | 22.3 [20.3, 24.9] | 22.0 [20.3, 24.5] | 22.6 [20.4, 25.1]  | 0.327   |
| Treatment center                   | Curie Paris | 287       | 167 (58%)              | 120 (42%)                 | 0.967   |
|                                   | Curie St Cloud | 160       | 92 (57%)               | 68 (42%)                  |         |
| Year of BC diagnosis               | 2011    | 23          | 10 (43%)               | 13 (57%)                  | 0.063   |
|                                   | 2012    | 31          | 22 (71%)               | 9 (29%)                   |         |
|                                   | 2013    | 51          | 36 (71%)               | 15 (29%)                  |         |
|                                   | 2014    | 69          | 33 (48%)               | 36 (52%)                  |         |
|                                   | 2015    | 109         | 62 (57%)               | 47 (43%)                  |         |
|                                   | 2016    | 96          | 60 (62%)               | 36 (38%)                  |         |
|                                   | 2017    | 68          | 36 (53%)               | 32 (47%)                  |         |
| Hereditary predisposition          | No      | 240         | 156 (65%)              | 84 (35%)                  | 1.000   |
|                                   | Yes     | 70          | 46 (66%)               | 24 (34%)                  |         |
| Clinical tumor size (mm)           | 31.5 (20.3) | 32.2 (20.2%) | 30.6 (20.4)            | 0.428   |
| Clinical T stage (TNM)             | T0-T1   | 178         | 94 (53%)               | 84 (47%)                  | 0.168   |
|                                   | T2      | 217         | 135 (62%)              | 82 (38%)                  |         |
|                                   | T3-T4   | 51          | 29 (57%)               | 22 (43%)                  |         |
| Clinical N stage (TNM)             | N0      | 281         | 163 (58%)              | 118 (42%)                 | 1.000   |
|                                   | N1-N2-N3 | 165       | 95 (58%)               | 70 (42%)                  |         |
| SBR grade                          | Grade I | 16          | 11 (69%)               | 5 (31%)                   | 0.212   |
|                                   | Grade II | 150        | 94 (63%)               | 56 (37%)                  |         |
|                                   | Grade III | 278     | 153 (55%)              | 125 (45%)                 |         |
| BC subtype                         | Luminal | 208         | 120 (58%)              | 88 (42%)                  | 0.609   |
|                                   | TNBC    | 92          | 64 (69%)               | 38 (41%)                  |         |
|                                   | HER2+/HR | 75          | 48 (64%)               | 27 (36%)                  |         |
|                                   | HER2+/HR | 28          | 14 (50%)               | 14 (50%)                  |         |
| Histological type                  | NST     | 426         | 246 (58%)              | 180 (42%)                 | 0.591   |
|                                   | Lobular | 8           | 6 (75%)                | 2 (25%)                   |         |
|                                   | Others  | 13          | 7 (54%)                | 6 (46%)                   |         |
| Neoadjuvant chemotherapy           | No      | 201         | 115 (57%)              | 86 (43%)                  | 0.853   |
|                                   | Yes     | 246         | 144 (59%)              | 102 (41%)                 |         |

Values in bold are the significant values.
with their doctors and only 19% of the patients had FP procedures. More characteristics of the healthcare providers are recommended to be analyzed and discussed, such as their knowledge about FP procedures, or how much time spent for each communication on FP with patients would be of major interest to further understand determinants associated with physician’s related barriers and facilitators.

This work has several clinical implications and identifies areas in which there is room for improvement. It highlights a patient population with unmet needs regarding information on FP (patients in their late 30s who already have children). It also calls for better training for healthcare providers to raise awareness on this topic, particularly among male doctors, through seminars (27), joint training with reproductive medicine experts (28), or the development of FP networks (29).

Prestructured fields in the EHR may be pertinent tools for preventing omissions and could provide an alert in real time, prompting such discussion. Alerts of this type have already proved effective for preventing drug interactions and are currently used in this context (30, 31). A similar reminder could be issued for all women of childbearing age receiving gonadotoxic treatment, to improve oncofertility practices in

FIGURE 3  |  Factors associated with fertility preservation procedures. (A) Age at diagnosis; (B) Children; (C) Neoadjuvant chemotherapy; (D) MCA for fertility preservation procedures*. *The red ellipse represents the concentration of patients who did not undergo fertility preservation procedures, whereas the blue ellipse represents the concentration of patients who underwent fertility preservation procedures.
cancer care. To clear the delineation of who is responsible for discussing the infertility risk associated with chemotherapy, the discussion could be done at the first consultation, which would facilitate a better systematization of the information. Finally, providing patients with information directly, via posters or flyers in waiting rooms, patient advocacy, and communities could help to increase the proportion of patients who are informed and empowered, and able to decide independently whether or not they wish to undergo FPPs if it is possible, before receiving gonadotoxic treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Conceptualization, AH, AT, FR, and A-SH. Methodology, FC and A-SH. Software, JB, A-SH. Validation, AH, AT, VC, CaS, A-SH, and FR. Formal analysis, A-SH. Investigation, AH, AT, VC, J-YP, and J-GF. Data curation, AH, AT, CaS, and A-SH. Writing—original draft preparation, AH and A-SH. Writing—review and editing, AH, AT, CaS, EL, BG, AT, FC, EDU, EDa, J-YP, J-GF, FR, and A-SH. All authors contributed to the article and approved the submitted version.

FUNDING

The authors declare that this study is a part of The Young Breast Cancer Project. The Young Breast Cancer Project was funded by Monoprix. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

ACKNOWLEDGMENTS

We thank patients and physicians of Institut Curie, and all the people who worked on this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.701620/full#supplementary-material

REFERENCES

1. Le Cancer Du Sein - Les Cancers Les Plus Fréquents. Available at: https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-fréquents/Cancer-du-sein.
2. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast Cancer Before Age 40 Years. Semin Oncol (2009) 36(3):237–49. doi: 10.1053/j.seminoncol.2009.03.001
3. Partridge AH, Ruddy KJ. Fertility and Adjuvant Treatment in Young Women With Breast Cancer. Breast (2007) 16:175–81. doi: 10.1016/j.breast.2007.07.029
4. Roness H, Kalich-Philosoph L, Meirw. Prevention of Chemotherapy-Induced Ovarian Damage: Possible Roles for Hormonal and non-Hormonal Attenuating Agents. Hum Reprod Update (2014) 20(5):759–74. doi: 10.1093/humupd/dmu019
5. Shandley LM, Spencer JB, Fothgill A, Mertens AC, Manatunga A, Panomato E, et al. Impact of Tamoxifen Therapy on Fertility in Breast Cancer Survivors. Fertility Sterility (2017) 107(1):243–52.e5. doi: 10.1016/j.fertnstert.2016.10.020
6. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reincke J, Taylor HS, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. JCO (2018) 36(19):1994–2001. doi: 10.1200/JCO.2018.78.1914
7. Grynberg M, Mayeur Le Bras A, Hesters L, Gallot V, Frydman N. First Birth Achieved After Fertility Preservation Using Vitrification of In Vitro Matured Oocytes in a Woman With Breast Cancer. Ann Oncol (2020) 31(4):541–2. doi: 10.1093/annonc.mmaa005
8. Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, et al. Fertility- and Menopause-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer. JCO (2005) 23(22):5155–65. doi: 10.1200/JCO.2005.07.773
9. Duffy CM, Allen SM, Clark MA. Discussions Regarding Reproductive Health for Young Women With Breast Cancer Undergoing Chemotherapy. JCO (2005) 23(4):766-73. doi: 10.1200/JCO.2005.01.134
10. Lee S, Heytens E, Moy F, Oztavuculu S, Oktay K. Determinants of Access to Fertility Preservation in Women With Breast Cancer. Fertil Steril (2011) 95(6):1932–6. doi: 10.1016/j.fertnstert.2011.01.169
11. Plan Cancer 2014-2019 Préservation Fertilité - Recherche Google. Available at: https://www.google.com/search?q=plan+cancer+2014-2019+pr%C3%A9servation+fertilit%C3%A9&oq=plan+cancer+2014-2019+pr%C3%A9servation+fertilit%C3%A9&aq=fv=fv=chrome.69857%33338.86609%7resol=chrome%3DUTF8-8
12. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment Fertility Counseling and Fertility Preservation Improve Quality of Life in Reproductive Age Women With Cancer. Cancer (2012) 118(6):1710–7. doi: 10.1002/cncr.26459
13. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated Disappearance of Ovarian Follicles in Mid-Life: Implications for Forecasting Menopause. Hum Reprod (1992) 7(10):1342–6. doi: 10.1093/oxfordjournals.humrep.a137570
14. Female Age-Related Fertility Decline. Fertility Sterility (2014) 101(3):633–4. doi: 10.1016/j.fertnstert.2013.12.032
15. ConSeilé: Un Outil Permettant De Rentrer Dans Le Monde Du Big Data En Santé - PDF Free Download Available at: https://coek.info/pdf-conseil-un-outil-permettant-de-rentrer-dans-le-monde-du-big-data-en-sante.html.
16. Hammond MEH, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. JOP (2010) 6(4):195–7. doi: 10.1200/JOP.10.00033
17. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med (2014) 138 (2):241–56. doi: 10.5858/arcpa.2013-0953-SA
18. Elston CW, Ellis IO. Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience From a Large Study With Long-Term Follow-Up. Histopathology (1991) 19(5):403–10. doi: 10.1111/j.1365-2559.1991.tb00229.x
19. Labrosse J, Lam T, Sebbag C, Benque M, Abdennabi I, Merckelbagh H, et al. Text Mining in Electronic Medical Records Enables Quick and Efficient Identification of Pregnancy Cases Occurring After Breast Cancer. JCO Clin Cancer Inf (2019) 3:1–12. doi: 10.1200/CCI.19.00031
20. Korkidakis A, Lajkosz K, Green M, Strobino D, Velez MP. Patterns of Referral for Fertility Preservation Among Female Adolescents and Young Adults With Breast Cancer: A Population-Based Study. J Adolesc Young Adult Oncol (2019) 8(2):197–204. doi: 10.1089/jayao.2018.0102

21. AMP-Avis-CNGOF-Limites-Age-07-02-21.Pdf. Available at: http://www.cngof.net/Medias-CNGOF/Communiques/2021/AMP-Avis-CNGOF-limites-age-07-02-21.pdf.

22. Marklund A, Lundberg FE, Eloranta S, Hedayati E, Pettersson K, Rodriguez-Wallberg KA. Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation. JAMA Oncol (2021) 7(1):86–91. doi: 10.1001/jamaoncol.2020.5957

23. Awad AT, el-Husseini G, Anwar M, Abu-Nasr A, Anwar AA, Sakr M. Bilateral Primary Breast Cancers: A Clinicopathological Study of the Second Primary. Int Surg (1996) 81(1):57–60. doi: 10.11604/pamj.2016.25.121.9967

24. Ben Charif A, Bouhnik A-D, Rey D, Provansal M, Courbiere B, Spire B, et al. Satisfaction With Fertility- and Sexuality-Related Information in Young Women With Breast Cancer—ELIPPSE40 Cohort. BMC Cancer (2015) 15(1):572. doi: 10.1186/s12885-015-1542-0

25. Covelli A, Facey M, Kennedy E, Brezden-Masley C, Gupta AA, Greenblatt E, et al. Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer. JAMA Netw Open (2019) 2(11):e1914511. doi: 10.1001/jamanetworkopen.2019.14511

26. Patel P, Kohn TP, Cohen J, Shiff B, Kohn J, Ramasamy R. Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey. JAMA Netw Open (2020) 3(7):e2010806. doi: 10.1001/jamanetworkopen.2020.10806

27. Forman EJ, Anders CK, Behera MA. A Nationwide Survey of Oncologists Regarding Treatment-Related Infertility and Fertility Preservation in Female Cancer Patients. Fertil Steril (2010) 94(5):1652–6. doi: 10.1016/j.fertnstert.2009.10.008

28. Adams E, Hill E, Watson E. Fertility Preservation in Cancer Survivors: A National Survey of Oncologists’ Current Knowledge, Practice and Attitudes. Br J Cancer (2013) 108(8):1602–15. doi: 10.1038/bjc.2013.139

29. Préaubert L. Préservation De La Fertilité En Oncologie : Bilan Des Pratiques En Région PACA-Corse. Journal de Gynécologie Obstétrique et Biologie de la Reproduction (2013) 6.

30. Phansalkar S, Zachariah M, Seidling HM, Mendes C, Volk L, Bates DW. Evaluation of Medication Alerts in Electronic Health Records for Compliance With Human Factors Principles. J Am Med Inform Assoc (2014) 21(e2):e332–40. doi: 10.1136/amiajnl-2013-002279

31. Capan M, Hoover S, Miller KE, Pal C, Glasgow JM, Jackson EV, et al. Data-Driven Approach to Early Warning Score-Based Alert Management. BMJ Open Qual (2018) 7(3):2399–6641. doi: 10.1136/bmjmq-2017-000088

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.